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Abstract
Anandamide (N-arachidonoylethanolamine, AEA) is an endogenous lipid that binds to cannabinoid
receptors in the central nervous system and in peripheral cells. Quantitative analysis of AEA is
generally based on the normalization to the fresh weight of the samples. Here, we show that the
normalization procedure of AEA content is such a critical factor, that it might introduce per se
significant discrepancies in the quantification of AEA even in the same sample. We suggest that a
rapid, accurate and most reliable reference to quantify AEA and congeners from different sources
is the protein content, a common parameter to cells and tissues.
Findings
Anandamide and the other "endocannabinoids" are en-
dogenous ligands for "brain-type" (CB1) and "spleen-
type" (CB2) cannabinoid receptors [1]. Also "non-classi-
cal" cannabinoid receptors and vanilloid receptors are ac-
tivated by AEA [2], which plays a number of roles with
potential clinical relevance, both in the central nervous
system and in the periphery [1,3]. In view of the broad im-
plications of AEA as central and peripheral modulator, its
quantification is of utmost importance, also for the con-
sideration that inhibition of AEA degradation via uptake
and hydrolysis might open new therapeutic perspectives
[1,3]. AEA content has been measured in pig, sheep and
cow brain [4], in rat brain and rat peripheral tissues [5–7],
in human brain and human cells in culture [8], and in
mouse brain [9]. Most quantitative analyses of AEA con-
tent have been made by gas chromatography/mass spec-
trometry (GC/MS) after prepurification of the lipid
extracts, and normalized to the fresh weight of the sam-
ples. This quantification has yielded concentration values
in the range 0.2 – 30 pmol/g fresh weight [4–7]. Recently,
we have developed a GC/MS procedure for the direct anal-
ysis of lipid extracts without prepurification steps [8,9].
Moreover, we normalized the amounts of AEA to the pro-
tein content of the samples, in order to better compare dif-
ferent tissues and cells, and also in consideration of the
fact that determination of proteins is much more reliable
than that of fresh weight. Using this direct GC/MS analysis
we found concentrations of AEA in the 340 – 400 pmol/
mg protein range [8,9]. Here, we show that, besides the
procedure adopted, the normalization of AEA content is a
critical factor, which might induce significant differences
in the same sample. Most notably, we show how applying
the same normalization procedure very similar or even
identical amounts of AEA are found in tissues and in cells
independently of their origin, suggesting that this com-
pound is evenly distributed in animals.
AEA was determined in rat brain, mouse brain, human
neuroblastoma CHP100 cells and human lymphoma
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U937 cells [8,9], and its content was then normalized to 1
mg of protein, DNA or lipid phosphorus, to fresh weight,
or to the cell number. Different aliquots of the same sam-
ple were used for these assays. While it is obvious that a
different normalization method may yield very different
values of AEA in the same sample (~12 to 50-fold lower
when AEA was normalized to fresh weight or cell number,
as compared to protein or DNA content), it is noteworthy
that normalization to a common parameter yielded simi-
lar or even identical levels of AEA in all samples tested (Ta-
ble 1). In particular, normalization to DNA content
yielded the same amounts of AEA in rat and mouse brain,
but approximately half that value in both tumor cells (Ta-
ble 1). This finding seems in agreement with the fact that
these cells are rapidly growing, and hence they have more
DNA. Instead, normalization to fresh weight showed S.D.
values of ~40%, in line with previous reports [4–7],
whereas normalization to the other parameters showed
S.D. values of ~15–20% only (Table 1). This observation
might reflect the large variability of water content among
the different samples.
Taken together, the present observation might represent a
caveat to researchers when they report on the content of a
metabolite, also by using newly developed liquid chroma-
tography/mass spectrometry techniques [10]. On the oth-
er hand, the present results suggest that the most reliable
reference to quantify AEA and congeners from different
sources is the protein content. In fact, it is a parameter
common to cells and tissues, which is easy and rapid to
measure with accuracy and reproducibility, even in tiny
samples.
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Table 1: Impact of Different Normalizations on the Quantification of Anandamide in Brain, and in Human Cells
Anandamide content Rat brain Mouse brain Neuroblastoma CHP100 cells Lymphoma U937 cells
pmol/mg protein 350 ± 70 400 ± 75 340 ± 65 400 ± 70
pmol/mg DNA 700 ± 98 800 ± 160 380 ± 70 440 ± 80
pmol/mg Pia 1.4 ± 0.3 1.6 ± 0.3 2.1 ± 0.4 3.3 ± 0.7
pmol/mg FWb 14 ± 5.6 16 ± 6.4 27 ± 9.7 28 ± 10.5
pmol/106 cells N.D.c N.D.c 19 ± 41 8  ± 4
Values are reported as the mean ± S.D. of 6 to 8 independent determinations, each performed in duplicate. aPi, lipid phosphorus; bFW, fresh weight; 
cN.D., not determined.